Ipca Laboratories Limited
Momentum (83/100) does the heavy lifting; valuation (36/100) is the drag.
Fair valueIpca Laboratories Limited earns a Buy from StocksWizard, with a blended score of 63/100. We put fair value near ₹1,384.26; at ₹1,774.5 that leaves roughly 22% downside, so the stock screens overvalued by 22%. On 36.0x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. The price is about 7% below its 52-week high of ₹1,900.6 and 40% above the low of ₹1,268.7. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 8/9. The average analyst target of ₹1,719.61 implies about 3% downside across 18 analysts. It clears 9 of 13 investability checks, with durability 69, valuation 58 and momentum 83 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,107.41.
Analyst views
1-year price
EOD · 2026-07-2952-week range
-6.63% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy63Piotroski F-score 8/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 13.2%
- Pass: Low debt (D/E < 0.5): 0.08x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: 6%
- Pass: Earnings growing: 342%
- Pass: Net margin ≥ 10%: 11.8%
- Pass: Current ratio > 1.5: 2.76
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 10.47
- Pass: Piotroski ≥ 7: 8/9
Quarterly results
Annual financials
Shareholding
- Promoter45.1%
- Institutions45.2%
- Public & other9.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 10.47.
- High Piotroski quality score (8/9).
Opportunities
- Earnings growing (342% YoY).
Bear case
Threats
- Trades ~22% above our estimated fair value.
About Ipca Laboratories Limited
Ipca Laboratories manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients across multiple therapeutic areas including anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic segments. The company operates globally, serving markets in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia through both generic and branded formulations.
Ipca Laboratories Limited — frequently asked questions
Is Ipca Laboratories Limited a buy, hold or sell?
StocksWizard currently rates Ipca Laboratories Limited (IPCALAB) a Buy, based on a blended score of 63/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Ipca Laboratories Limited's fair value?
Our blended DCF and relative-valuation model estimates Ipca Laboratories Limited's fair value at about ₹1,384.26, versus a current price of ₹1,774.5 — roughly 22% downside. On that basis the stock looks overvalued by 22%.
Is Ipca Laboratories Limited financially healthy?
Ipca Laboratories Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 8/9.
How has Ipca Laboratories Limited's share price performed?
Ipca Laboratories Limited is up 16% over three months, and last traded at ₹1,774.5. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.